Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners

Visus Therapeutics获得了2000万美元的额外融资,由新投资者LSP牵头,Sage Partners参与

2021-08-10 20:30:13 BioSpace


Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Directors with the addition of John de Koning of LSP, a seasoned pharmaceutical executive with almost 30 years of scientific and management expertise Will Host its first Capital Markets Day in New York City on August 31, 2021 SEATTLE--(BUSINESS WIRE)-- Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced the closing of $20 million in preferred stock financing, led by LSP in Amsterdam, along with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation - JJDC, Inc. and other inside investors in the Company. In conjunction with this financing, John de Koning, Ph.D., a General Partner at LSP, has joined the Company’s Board of Directors. “This financial milestone comes in advance of the Phase 2 topline readout of our lead clinical candidate, BRIMOCHOL™, in development for the treatment of presbyopia,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Financing from LSP, one of Europe’s leading investment firms, and Sage Partners expands our base of global investors and will support our drug development and commercial efforts to meet unmet patient needs.” BRIMOCHOL is an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. It is a proprietary formulation that combines two well-studied, FDA-approved pharmaceuticals: carbachol and brimonidine. BRIMOCHOL has been studied in more than 200 patients across six clinical studies. Topline data from a Phase 2 clinical study evaluating BRIMOCHOL for the treatment of presbyopia are expected in the second half of 2021 and, pending affirmative results, the company plans to immediately initiate pivotal Phase 3 studies. “I’m particularly excited to welcome John de Koning to our Board and leverage his unparalleled scientific, business and management acumen as we advance BRIMOCHOL into late-stage clinical trials and prepare our commercial strategy,” continued Bergo. “John’s decades of leadership experience advising life science companies will be invaluable as we continue to develop a robust portfolio of novel therapies that promise to set new standards of care in ophthalmology.” As one of Europe’s leading investors in the healthcare sector, John de Koning brings a wealth of knowledge and industry experience to his role on Visus Therapeutics’ Board of Directors. For more than a decade, he was the organizer of BioCapital Europe, which is regarded as Europe’s premier annual life sciences investment conference. “After evaluation of several companies in the presbyopia-correcting eye drop category, we are pleased to invest in Visus Therapeutics and help bring what we believe to be a best-in-class treatment in this category to the global markets,” said John de Koning. “I’m looking forward to partnering with my fellow board members and the entire Visus Therapeutics management team to deliver BRIMOCHOL and other exciting ophthalmic therapeutics to patients.” The company recently announced that it will be hosting its debut Capital Markets Day on August 31 in New York City and virtually for investors and media. More information is available at the Visus 2021 Capital Markets Day registration site. About Presbyopia Presbyopia is the loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins when adults are in their 40s and becomes almost universal by age 50.1 Presbyopia impacts billions of people globally with approximately 123 million adults affected in the U.S. alone. 2 Reading glasses are the most common solution for near-vision correction. However, many people often find glasses inconvenient and/or prefer not to wear them for aesthetic reasons. Currently, there are no FDA-approved medications for presbyopia. About Visus Therapeutics Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates. For more information, visit: and follow us on LinkedIn, Twitter (@VisusTx) and Instagram. 1 Care of the Patient with Presbyopia. American Optometric Association. 2011. 2 Market Scope. Global Presbyopia-Correcting Surgery Market Report. April 2012. View source version on Media: Business & Biotech Press: Doug Hochstedler (317) 645-8665 Investor Relations: Paul Sagan (617) 865-0041 Eye Care Trade Press: Michele Gray (917) 449-9250 Source: Visus Therapeutics Inc. View this news release online at:
所得款项将支持铅资产Brimochol™正在调查的老花眼临床和商业努力,以及该公司药物开发管道中的新研发活动 增加了LSP的约翰·德·科宁(John de Koning),他是一位经验丰富的制药高管,拥有近30年的科学和管理专业知识,加强了董事会 将于2021年8月31日在纽约市举办首个资本市场日 西雅图--(商业网)--维苏治疗公司,一家临床阶段的制药公司,专注于开发创新眼科疗法,以改善世界各地的人们的视力,今天宣布结束2000万美元的优先股融资,由阿姆斯特丹的LSP牵头,香港的Sage Partners公司、强生创新-JJDC公司和该公司的其他内部投资者参与。与这笔融资有关的是,LSP的普通合伙人约翰·德·科宁博士也加入了该公司的董事会。 Visus Therapeutics公司的联合创始人兼首席执行官本·伯格(Ben Bergo)表示:“这一财务里程碑是在我们的主要临床候选人布里莫乔·™(Brimochol Simon)开发治疗老花眼的第二阶段背线读数之前取得的。”“欧洲领先的投资公司之一LSP和Sage Partners的融资扩大了我们的全球投资者基础,并将支持我们的药物开发和商业努力,以满足未满足的患者需求。” BRIMOCHOL是一种研究性药物,设计为每日一次的眼药水,以纠正与老花眼相关的近视力损失。它是一种专利制剂,结合了两种经过充分研究的FDA批准的药物:卡巴胆碱和溴莫尼定。BRIMOCHOL已经在六项临床研究中对200多名患者进行了研究。评估BRIMOCHOL治疗老花眼的2期临床研究的Topline数据预计将于2021年下半年发布,在获得肯定结果之前,该公司计划立即启动关键的3期研究。 伯格继续说:“我特别兴奋地欢迎约翰·德·科宁加入我们的董事会,并在我们推进BRIMOCHOL进入后期临床试验并准备我们的商业战略时,利用他无与伦比的科学、商业和管理头脑。”“约翰为生命科学公司提供建议的几十年领导经验将是无价的,因为我们继续开发一系列强大的新疗法,有望设定眼科护理的新标准。” 作为欧洲医疗保健行业的主要投资者之一,约翰·德·科宁为他在Visus Therapeutics董事会的角色带来了丰富的知识和行业经验。十多年来,他一直是BioCapital Europe的组织者,该会议被认为是欧洲首屈一指的年度生命科学投资会议。 约翰·德·科宁说:“在评估了几家老花矫正眼药水类别的公司后,我们很高兴投资于Visus Therapeutics,并帮助将我们认为是该类别中最好的治疗方法推向全球市场。”“我期待着与我的董事会成员和整个Visus治疗管理团队合作,为患者提供BRIMOCHOL和其他令人兴奋的眼科治疗。” 该公司最近宣布,将于8月31日在纽约市举办首次资本市场日,几乎面向投资者和媒体。更多信息可在Visus 2021资本市场日注册网站获得。 关于老花眼 老花眼是与衰老相关的近视力损失,使其难以执行阅读小字等任务。它通常从成年人40多岁开始,到50岁时几乎变得普遍。老花眼影响了全球数十亿人,仅在美国就有约1.23亿成年人受到影响。2老花镜是近视眼矫正最常见的解决方案。然而,许多人往往觉得眼镜不方便和/或出于审美原因宁愿不戴眼镜。目前,没有FDA批准的治疗老花眼的药物。 关于Visus治疗学 Visus Therapeutics是一家临床阶段的公司,专注于开发创新的眼科疗法,为世界各地的人们改善视力。该公司在西雅图和加州奥兰治县设有办事处,主要临床候选药物是BRIMOCHOL,这是一种研究性药物,旨在每天滴一次眼药水,以纠正与老花眼相关的近视力损失。同时,Visus Therapeutics专注于推进其早期眼科候选产品的管道。欲了解更多信息,请访问,并在领英、推特(@visustx)和Instagram上关注我们。 1老花眼患者的护理。美国视光协会。2011年。 2市场范围。全球老花矫正手术市场报告。2012年4月。 在businesswire.com查看源代码版本: 媒体: 商业与生物技术出版社: 道格·霍赫斯特德勒 (317)645-8665 投资者关系: 保罗·萨根 (617)865-0041 眼科护理行业出版社: 米歇尔·格雷 (917)449-9250 资料来源:Visus Therapeutics Inc. 在网上查看此新闻稿: